Daily Stock Analysis, BPMX, Biopharmx Corp, priceseries

Biopharmx Corp. Daily Stock Analysis
Stock Information
Open
6.02
Close
6.12
High
6.30
Low
5.47
Previous Close
6.76
Daily Price Gain
-0.64
YTD High
112.50
YTD High Date
Jun 15, 2015
YTD Low
0.25
YTD Low Date
Mar 17, 2020
YTD Price Change
2.37
YTD Gain
63.20%
52 Week High
112.50
52 Week High Date
Jun 15, 2015
52 Week Low
0.25
52 Week Low Date
Mar 17, 2020
52 Week Price Change
2.37
52 Week Gain
63.20%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jan 11. 2017
10.30
Jan 12. 2017
11.02
1 Trading Days
7.05%
Link
LONG
Apr 5. 2017
13.00
Apr 26. 2017
17.62
14 Trading Days
35.55%
Link
LONG
Aug 30. 2017
7.28
Sep 13. 2017
7.90
9 Trading Days
8.65%
Link
LONG
Feb 26. 2018
4.48
Mar 14. 2018
7.09
12 Trading Days
58.32%
Link
LONG
May 25. 2018
5.67
Jun 5. 2018
6.03
6 Trading Days
6.17%
Link
LONG
Sep 10. 2018
4.03
Sep 28. 2018
4.92
14 Trading Days
22.05%
Link
Company Information
Stock Symbol
BPMX
Exchange
NYSE MKT
Company URL
http://www.biopharmx.com
Company Phone
650-889-5020
CEO
Anja B. Krammer
Headquarters
California
Business Address
1505 ADAMS DRIVE, SUITE D, MENLO PARK, CA 94025
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001504167
About

BioPharmX Corp. engages in providing healthcare products through platform technologies for pharmaceutical, over-the-counter and supplement applications in dermatology. The company was founded by James R. Pekarsky on August 30, 2010 and is headquartered in Menlo Park, CA.

Description

BioPharmX Corporation, a specialty pharmaceutical company, focuses on the development of novel drug delivery products for women's health and dermatology markets. The company offers prescription and over-the-counter (OTC) products in oral, topical, and injectable forms. It provides VI2OLET iodine, an OTC molecular iodine dietary supplement that addresses cyclic breast discomfort and for the alleviation of symptoms of fibrocystic breast condition (FBC). The company's clinical-stage product candidates include BPX03, a molecular iodine tablet for the treatment of benign breast pain associated with FBC and cyclic mastalgia; and BPX01, a topical antibiotic for the treatment of acne. It serves pharmaceutical companies; physician's practices, including obstetricians and gynecologists, dermatologists, and general practitioners; and retail customers through retail sales channels and/or pharmacy outlets. The company has collaboration and licensing agreement with Iogen LLC for the development of molecular iodine products; and collaboration and supply agreement with NuTech Medical, Inc. to develop products in the field of dermatology. BioPharmX Corporation is headquartered in Menlo Park, California.